# Efficacy and Safety of Two Doses of HIL-214 in Children

> **NCT05281094** · PHASE2,PHASE3 · TERMINATED · sponsor: **HilleVax** · enrollment: 3084 (actual)

## Conditions studied

- Gastroenteritis

## Interventions

- **BIOLOGICAL:** HIL-214
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05281094
- **Lead sponsor:** HilleVax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-28
- **Primary completion:** 2023-12-28
- **Final completion:** 2024-09-30
- **Target enrollment:** 3084 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05281094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05281094, "Efficacy and Safety of Two Doses of HIL-214 in Children". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05281094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*